Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Compare tax exposure between dividend ETFs and taxable funds in 2024 to identify the lower-tax option for your goals.
28,172 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
A once-sacrosanct pledge to never dump bitcoin treasury holdings is showing cracks as firms explore selling slices to...
Strategy unveiled a plan to repurchase roughly $1.5 billion of its 2029 notes, with funding options including Bitcoin...
Tech firms push AI deeper into operations even as layoffs rise. The result is growing anxiety among workers about job...
Salesforce unveiled a record $25 billion accelerated share repurchase funded by debt as it posted quarterly results. ...
Berkshire Hathaway is positioned to become a much larger Alphabet holder as the tech giant pursues a bold AI financin...
Entrepreneurship powered America’s rise, and Steve Case argues we must expand that engine nationwide to guard the cou...
A bipartisan plan to overhaul the USPS centers on drastic steps, including shutting down post office operations in se...
A dementia diagnosis reshapes retirement plans as custodial care bills far exceed medical costs and Medicare coverage...
Investors often chase big biotech gains, but Viking Therapeutics stock really hinges on milestones and cash runway. T...
Debt worries surround a proposed $1.5 trillion boost to the Pentagon budget, drawing pushback from fiscal hawks and r...
When a notable small-cap manager exits a large stake in a data-security firm, it creates questions for investors. Thi...